139 | 2 | 7 |
下载次数 | 被引频次 | 阅读次数 |
目的探讨中性粒-淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)对新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)患者预后评估的价值。方法采用回顾性研究的方法,选择收治的399例COVID-19为研究对象,根据临床预后,分为生存组(375例)和死亡组(24例),收集患者入科第1天中性粒细胞计数、淋巴细胞计数以计算NLR,比较中性粒细胞、淋巴细胞、NLR在不同组间的差异;采用受试者工作特征(ROC)曲线评价NLR预测预后的最佳阈值。结果死亡组的中性粒细胞、NLR明显高于生存组,死亡组的淋巴细胞计数明显低于生存组。通过ROC曲线分析发现中性粒细胞、淋巴细胞、NLR的ROC曲线下面积分别为0. 759、0. 838、0. 856,最佳工作点分别为4. 955×109/L、0. 775×109/L、6. 919。结论NLR可以作为一个简便有效的辅助指标用于COVID-19患者的预后评估。
Abstract:Objective To explore the assessment value of neutrophil-to-lymphocyte ratio(NLR) for prognosis in coronavirus disease 2019(COVID-19). Methods Using the retrospective study,399 cases of COVID-19 admitted to Wuhan Fourth Hospital were selected as the research subjects. According to the clinical prognosis,they were divided into the survival group(n = 375) and the death group(n = 24). The neutrophil count and lymphocyte count of patients on the first day of admission were collected to calculate the NLR,and the differences between neutrophils,lymphocytes and NLR in different groups were compared. The receiver-operating characteristic(ROC) curve was used to evaluate the optimal threshold of NLR for predicting prognosis. Results The neutrophils and NLR of the death group were significantly higher than that of the survival group, and the lymphocytes of the death group were significantly lower than that of the survival group.According to ROC curve analysis, the areas under the ROC curve of neutrophils,lymphocytes and NLR were 0. 759, 0. 838 and 0. 856, respectively, and the optimal thresholds were 4. 955 × 109/L,0. 775 × 109/L,and 6. 919,respectively. Conclusion NLR can be used as a simple and effective auxiliary indicator for prognostic evaluation of COVID-19 patients.
[1] HUANG X,WEI F,HU L,et al. Epidemiology and clinical characteristics of COVID-19[J]. Arch Iran Med,2020,23(4):268-271.
[2] LAI C,SHIH T,KO W,et al. Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and coronavirus disease-2019(COVID-19):the epidemic and the challenges[J]. Int J Antimicrob Ag,2020,55(3):105924.
[3]尚伟锋,李维,周登峰,等.新型冠状病毒肺炎临床特征的meta分析[J].临床荟萃,2020,35(4):293-296.
[4]李园园,王伟娜,雷宇,等.临床诊断新型冠状病毒肺炎中核酸检测阳性与阴性患者临床特征的比较[J].中华结核和呼吸杂志,2020,43(5):427-430.
[5]国家卫生健康委员会.截至3月2日24时新型冠状病毒肺炎疫情最新情况[EB/OL].(2020-03-03).http:∥www.nhc.gov.cn/yjb/s7860/202003/c588ee20113b4136b27f2a07faa7075b.shtml.
[6]国家卫生健康委办公厅.新型冠状病毒肺炎诊疗方案(试行第七版)[J].传染病信息,2020,33(1):1-6,26.
[7]张文福,何俊美,帖金凤,等.冠状病毒的抵抗力与消毒[J].中国消毒学杂志,2020(1):1-5.
[8] WANG D,HU B,HU C,et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J]. JAMA,2020,323(11):1061-1069.
[9] CHEN N,ZHOU M,DONG X,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J]. The Lancet,2020,395(223):507-513.
[10] HUANG C,WANG Y,LI X,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. The Lancet,2020,395:497-506.
[11] WU Z,MCGOOGAN J M. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China:summary of a report of 72314 cases from the chinese center for disease control and prevention[J]. JAMA,2020,323(13):1239-1242.
[12]孟欣,胡辽辽,张宁,等.中性粒细胞/淋巴细胞比值在甲、乙型流感病毒感染患者预测价值分析[J].国际检验医学杂志,2019,40(20):2464-2467.
[13]肖四方,潘建华,向延根. NLR、PLR和LMR在急诊甲、乙型流感病毒感染者中的临床意义[J].热带医学杂志,2018,18(11):1478-1481.
[14]贾超,蒋剑文,郭端,等.中性粒细胞与淋巴细胞比值在脓毒症诊断及预后评估中的作用[J].海南医学院学报,2019(19):1492-1495.
[15]肖暖,唐路宁,谭莉莉,等.中性粒细胞/淋巴细胞比率对急性心肌梗死患者住院死亡率的预测价值[J].中国现代医学杂志,2013,23(22):29-33.
基本信息:
DOI:10.16389/j.cnki.cn42-1737/n.2020.06.004
中图分类号:R563.1
引用信息:
[1]尚伟锋,李园园,宋小红等.中性粒-淋巴细胞比值评估新型冠状病毒肺炎预后的价值[J].江汉大学学报(自然科学版),2020,48(06):33-37.DOI:10.16389/j.cnki.cn42-1737/n.2020.06.004.
基金信息: